retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished ESC 2024: Retatrutide improves lipid

The combination of GLP-1's effect on insulin sensitivity and strength trainings ability to improve it can create a synergistic effect, making the body more efficient at using glucose and promoting fat loss while preserving muscle

A once-daily oral pill is far easier for many people than a weekly injection

Cost-per-mg varies 24 across suppliers for identical peptides

While Exe4 was undetectable in the culture medium after transfection of Exe4 alone, the fusion with FCS and SP effectively enhanced secretion, with the combination of NGF-FCS2 yielding the highest Exe4 secretion in both cell lines

H., Wang, C

Tirzepatide is a GIP and GLP-1 receptor antagonist that should be approved for weight loss this year by the FDA